FDA Release Letter Date Sept. 28: Sends Letter To Evolus, Terms Co.'s Claims About JEUVEAU As Misleading

On September 28, the FDA sent a letter to Evolus, stating that the company's claims regarding its product JEUVEAU were misleading. This communication could potentially impact Evolus's market position and credibility. The stock ticker for Evolus is EOLS.